Company Dossier · Health Care
AbbVie Inc.
- S&P 500
- S&P 100
- Russell 1000
What AbbVie Inc. is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $64.4 billion, up 10% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $18.2 billion, down 0.2% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $1.30 billion, up 25% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.98 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $3.99 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 31, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 2 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 20, 2026): 2 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $8.2 million on the open market.SEC Form 4
- 4,243 institutional managers reported a position at June 30, 2026 (+125 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 131 (123 a year earlier).U.S. Department of Labor (OFLC)
- Headlines in the last 30 days: 14, of which 3 read positive and 3 negative.Palanor headline tone
Risk events (12 months): 2 — latest OSHA inspection, Jun 25, 2026 →
Company Posture
How Company Posture is measured →What AbbVie Inc. is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending74th pct
- Debt raised68th pct
- Buybacks vs capex78th pct
- Hiring filings53rd pct
- Deals and private raises49th pct
- Patent publications20th pct
Confident ↔ Hedging
Mixed
- Call sentiment81st pct
- Call confidence78th pct
- Guidance changes3rd pct
- Risk factors added18th pct
- Insider open-market trades44th pct
- − Guidance changes
- + Call sentiment
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver62nd pct
- Stress filings48th pct
Credit
How these are built →AbbVie Inc.'s borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$70.8B
- Due within a year $8.3B
- Longer term $62.5B
- Default point $39.6B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
$26.0B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Aug 4, 2026 | $500M | 6.100% | 2066 (40y) | +92bp | 6.110% |
| Aug 4, 2026 | $1B | 5.450% | 2038 (12y) | +85bp | 5.471% |
| Aug 4, 2026 | $1.5B | 5.300% | 2036 (10y) | +70bp | 5.321% |
| Aug 4, 2026 | $500M | SOFR + 42bp | 2028 (2y) | — | — |
| Aug 4, 2026 | $1.25B | 5.050% | 2033 (7y) | +60bp | 5.068% |
| Aug 4, 2026 | $1.5B | 4.875% | 2031 (5y) | +55bp | 4.879% |
| Aug 4, 2026 | $1.25B | 4.650% | 2030 (4y) | +45bp | 4.691% |
| Aug 4, 2026 | $1B | 4.500% | 2028 (2y) | +32bp | 4.516% |
| Aug 4, 2026 | $1.5B | 6.000% | 2056 (30y) | +85bp | 6.040% |
| Feb 24, 2026 | $1.5B | 4.750% | 2036 (10y) | +73bp | 4.761% |
| Feb 24, 2026 | $500M | 5.650% | 2066 (40y) | +98bp | 5.668% |
| Feb 24, 2026 | $750M | SOFR + 48bp | 2028 (2y) | — | — |
From the pricing term sheets AbbVie Inc. filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
News
AbbVie Inc.: headline tone
Net share of positive headlines, trailing 28 days, −1 to +1
In the news
Headlines that name AbbVie Inc., with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- PositiveAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
Endpoints News · Oct 19, 2026
- NegativeHospital group sues to stop 340B rebate pilot again (ABBV:NYSE)
seekingalpha.com · via Marketaux · Oct 10, 2026
- NegativeAbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
gurufocus.com · via Marketaux · Oct 6, 2026
- PositiveAbbVie, Genmab Epkinly wins late-stage lymphoma trial
Palanor Wire · Oct 6, 2026
- NeutralDual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive · Oct 6, 2026
- NeutralAbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
Endpoints News · Oct 6, 2026
- NeutralAbbVie (ABBV) Flags $216M Q3 Charge Impacting Earnings Amid Dividend Focus
gurufocus.com · via Marketaux · Oct 5, 2026
- NeutralAbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
insidermonkey.com · via Marketaux · Oct 4, 2026
- NeutralAbbVie among participants in new 340B rebate pilot (ABBV:NYSE)
seekingalpha.com · via Marketaux · Oct 3, 2026
- NeutralAbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Highlights Dividend Concerns
gurufocus.com · via Marketaux · Oct 1, 2026
- NeutralAbbVie long-term data buoys Rinvoq for vitiligo
seekingalpha.com · via Marketaux · Oct 1, 2026
- NegativeAbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
Endpoints News · Sep 30, 2026
- NeutralAbbVie's Zumilokibart Phase 2 Success Highlights Dividend Sustainability Concerns (ABBV)
gurufocus.com · via Marketaux · Sep 30, 2026
- PositiveSTAT+: AbbVie wins FDA nod for Parkinson’s pill
STAT · Sep 28, 2026
- NeutralTrailing rivals, AbbVie scores win with dual-acting myeloma drug
BioPharma Dive · Sep 4, 2026
- Neutral
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (FEDERAL STREET STRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ABBVIE, INC.)third_quarter 2026 · $1.1 million
- Oct 20, 2026LobbyingLobbying report (W STRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ACG ADVOCACY)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (BAKER & HOSTETLER LLP)third_quarter 2026
- Oct 15, 20268-KDirector or officer changeItem 5.02
- Aug 25, 2026Patent
- Aug 25, 2026Patent
- Jun 25, 2026Risk event
- May 12, 20268-KShareholder vote resultsItem 5.07
- May 12, 2026Patent
- Mar 10, 2026Patent
- Feb 20, 202610-KAnnual report (10-K)2 risk factors added, 0 removed
- Dec 23, 2025Patent
- Dec 9, 2025Risk event
- May 13, 20258-KDirector or officer changeItem 5.02
- May 13, 20258-KShareholder vote resultsItem 5.07
- Feb 14, 20258-KDirector or officer changeItem 5.02
- Feb 14, 202510-KAnnual report (10-K)0 risk factors added, 1 removed
- Feb 3, 2025Risk event
- Jan 10, 20258-KMaterial impairmentItem 2.06
- Dec 13, 20248-KDirector or officer changeItem 5.02
- Feb 20, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Pfizer Inc. PFE | $63.7B | $11.0B | Jun 28, 2026 |
| Merck & Co. MRK | $66.6B | $16.1B | Jun 30, 2026 |
| HCA Healthcare HCA | $76.4B | $7.9B | Mar 31, 2026 |
| Eli Lilly and Company LLY | $79.7B | — | Jun 30, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Thermo Fisher Scientific TMO | $46.3B | $7.3B | Jun 27, 2026 |
| Abbott Laboratories ABT | $45.1B | $7.4B | Mar 31, 2026 |
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |